Brand Name or Equal to Agilent 5100 ICP-OES for FDA
Department of Health and Human Services, Food and Drug Administration | Published March 31, 2016 - Deadline April 8, 2016
COMBINED SYNOPSIS/SOLICITATION FOR A BRAND NAME OR EQUAL TO AGILENT 5100 ICP-OES FOR FDA SOLICITATION NUMBER: FDA-SOL-1163252
This is a combined synopsis/solicitation for commercial items prepared in accordance with the Federal Acquisition Regulation (FAR) format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued.
The solicitation number is FDA-SOL-1163252. This solicitation is issued as a Total Small Business Set, Request for Quote (RFQ). The solicitation documented and incorporated provisions and clauses in effect through the Federal Acquisition Circular (FAC) FAC 2005-87-1, Effective 16 March 2016.The associated North American Industry Classification System (NAICS) Code is - 334516 - Analytical Laboratory Instrument Manufacturing; Small Business Size Standard is 500 Employees.The US Food & Drug Administration (FDA) intends to issue a Commercial Item Firm Fixed-Price purchase order that meets the following specifications below. SUPPLIES OR SERVICES AND PRICES/COSTSThe contractor shall fill out the following pricing sheet:CLIN Description Qty Unitof Issue Price1 Automated Dual View Inductively Coupled Plasma Optical Emission Spectrometry System (DV ICP-OES) 1 Each $2 Optional Item - Automated Dual View Inductively Coupled Plasma Optical Emission Spectrometry System (DV ICP-OES) 1 Each $Total Amount $
STATEMENT OF WORK (SOW)
I. General Description of Need
The Kansas City District Laboratory requires an Automated Dual View Inductively Coupled Plasma Optical Emission Spectrometry System (DV ICP-OES), such as the Agilent 5100 ICP-OES or equivalent with the option to buy a second one within the first base period of the contract. The instrument is used to support elemental analysis for toxic and nutritional elements such as arsenic, lead, cadmium, iron, and cobalt in food and dietary supplements. This instrument supports regulatory sample analyses and Total Diet Study analyses. The contractor shall also provide instrument peripherals, including the Agilent SPS 3 Autosampler, and the Agilent G8481A Chiller or equivalent.
II. Salient Characteristics
All of the following are minimum requirements. Equivalent requirements that differ from these minimum requirements must be justified by the proposing vendor and evaluated by the Government. The Automated Dual View (Axial and Radial) Inductively Coupled Plasma-Optical Emission Spectrophotometers with Automated Data Systems (DV ICP-OES) instrument shall "meet or exceed" the following salient characteristics/specifications.
**Offerors shall address each of the salient characteristics in order to be considered**
• The system mainframe must be a compact, bench-top design.• Simultaneous dual view plasma allowing radial and axial view analysis at the same time without sacrificing radial view sensitivity is required.• The instruments must be capable of analysis of UV and Visible elements simultaneously without separate wavelength reading.• The instruments must be fully functional at 10.0 L/Min of argon when the plasma is on as argon gas (consumable) is expensive thus an instrument designed to minimize argon flow is desirable.• The instruments must be capable of data capture for all wavelengths of all elements on each sample tested within a batch.• The instrument must allow analyst to quickly and easily remove the torch, injector, spray chamber and nebulizer for maintenance.• The instrument must have automated alignment of the torch and optics. Controlled X-Y viewing position to the torch for rapid alignment for "best" viewing position-(critical for axial view systems).• The instrument must have a thermostatically controlled environment for the instrument's optics to eliminate problems associated with variable room temperatures, including but not limited to wavelength shifts.• The instruments must have wavelength flexibility to enable analysis of any ICP element at multiple wavelengths.• The instruments must have a True Solid-State Radio Frequency Generator or equivalent technology.• Wavelength Resolution must reach 0.0045 nm for the peak separation to reduce spectral interferences inter-element corrections.• To reduce the need for rerun analysis the reprocessing of the original "RAW" data must be a feature of the instrument. The reprocessing must be available while instrument is running next sample set.• Each instrument must have the capability of storing (housing) the original "raw" data and archiving analyses results of "raw" data which allows spectra viewing at any time--this feature allows analysts to retroactively determine the concentrations of elements not in the original method or at alternate wavelengths.• The instrument must have capabilities to support auto start and auto stop functions. The warm-up period shall not exceed 30 minutes.• The system must have the capability to automatically export data and import data from the analysis to an Excel Worksheet, Laboratory Information Management System, or any other laboratory data management system once analysis are completed.• Must be able to dynamically add to autosampler run lists even after an analysis has started.• The instrument hardware and software must allow for the creation of methods, sample files, reprocessing, examination of spectra, and data review while the instrument simultaneously collects data and runs samples.• Reprocessing must allow method parameters to be changed after data collection to determine if the changes are appropriate for samples without changing original data.• The instrument software must have inter-element correction model builder. That allows the analyst to create models from stored data and also allows the analyst to test these models without having to analyze the samples and standards over and over.• Each instrument must include autosampler, computer hardware and software, and printer. The instrument must include separate chilled water recirculator (separate chiller allows for placement away from the instrument to reduce noise in the working environment, separate chiller eliminates the potential for a leak to occur in the instrument, causing a safety hazard).• A copy of the method is saved with each set of data to provide an audit trail of the conditions used to perform the analyses in the event there is a question at a later time.• The system shall be delivered with all necessary supplies and accessories required for installation and start-up including standards for setting up the detector, standards for verifying instrument performance, tubing and fitting• Installation and one day of on-site familiarization operational training shall be included.• The instrument must be a newly manufactured unit, not used and refurbished or previously used for demonstration.• The system must be warranted for parts and labor for 12 months from the date of installation and shall include at a minimum: coverage on all non-consumable items and parts supplied with unlimited on-site service visits with a maximum 48-hour onsite response time, factory-certified replacement parts, engineer labor and travel costs, software updates and notifications.
All labor, replacement parts and components (excluding consumables) shall be guaranteed.
III. Period of Performance
The period of performance shall be for a base period of twelve (12) months with an optional item to be purchased within the base period.
IV. Government Furnished Property
The Government shall provide visitor's access to the FDA facilities during the performance of the contract.
A. Special instructionsThe offeror shall include sufficient details on the technical specifications in order for a determination to be made as to whether the offeror meet all the technical requirements identified in the solicitation.
Place(s) of Delivery: Kansas City District Laboratory, ORAFood and Drug Administration (FDA)11510 West 80th StreetLenexa, KS 66214
Hours of Operation:
The Contractor will be responsible for delivering equipment between the hours of 8:00 am - 4:00 pm Monday thru Friday except Federal Holidays.When vendor arrives on site to deliver and install equipment, they will need to check in with the Front Security Guards and provide proper identification. They will receive an "Escort Required" temporary badge, which must be worn at all times in the building and will need to stay with lab personnel during their visit. If vendors need to enter into the laboratory, safety glasses must be worn. When their work is complete, they will check out with the same Security Guards, turning in their temporary badge. Tobacco, of any form, is not permitted on Federal Property, in Federal Buildings or parking lots.
The following FAR and HHSAR clauses apply to this acquisition. FAR clauses and provisions can be obtained at https://www.acquisition.gov/far/index.html.
The provision at 52.212-1, Instructions to Offerors-Commercial Items (Apr 2014), applies to this acquisition with the following addenda to the provision.
Period for Acceptance of Offers: The offeror agrees to hold the prices firm through September 30, 2016.The provision at 52.212-2, Evaluation-Commercial Items (Jan 1999), is applicable to this requirement. The specific evaluation criteria to be included in paragraph (a) of that provision are as follows:
The Government will award a contract resulting from this solicitation to the responsible offeror whose proposal meets the specifications listed under Part 3 of this solicitation and is the lowest priced proposal received in response to this solicitation. Therefore, award will be made to offeror whose proposal is determined to be Lowest Price Technically Acceptable.
A written notice of award or acceptance of an offer mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award.
The Provision at FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Mar 2015), applies to this acquisition. An offeror should complete only paragraph (b) of this provision if the offeror has completed the annual representations and certifications electronically at http://orca.bpn.gov.
The clause at 52.212-4, Contract Terms and Conditions-Commercial Items (May 2015), applies to this acquisition with the following addenda:
A. The contractor shall submit one original copy of each invoice to the address specified below:
Office of Financial ServicesFood and Drug AdministrationW032- Second FloorMAIL HUB 214510903 New Hampshire AvenueBldg 32, Rm# 2162, Mail Hub 2145Silver Spring MD 20993-0002Attn: Vendor Payments(301) 827-3742 or (866) email@example.com
B. The contractor shall submit one electronic copy of the invoice to each of the recipients listed below:
Project Officer: TBDEmail:
Contract Specialist: Corina GensonEmail: Corina.Genson@fda.hhs.gov
Invoices submitted under this contract must comply with the requirements set forth in FAR Clauses 52.232-25 (Prompt Payment) and 52.232-33 (Payment by Electronic Funds Transfer - System for Award Management) and/or applicable Far Clauses specified herein. To constitute a proper invoice, the invoice must be submitted on company letterhead and include each of the following:
(I) Name and address of the contractor; (II) Invoice Date and Invoice Number; (III) Purchase order/Award Number; (IV) Description, Quantity, Unit of Measure, Unit Price, and Extended Price Supplies Delivered or Services Performed, including: (a) Period of Performance for which costs are claimed; (b) Itemized travel costs, including origin and destination; and (c) Any other supporting information necessary to clarify questionable expenditures;(V) Shipping number and date of shipping, including the bill of lading number and weight of shipment if shipped on government bill of lading; (VI) Terms of any discount for prompt payment offered; (VII) Name and address of official to whom payment is to be sent (must be the same as that in the purchase order/award, or in a proper notice of assignment)(VIII) Name, title and phone number of person to notify in event of defective invoice; (IX) Taxpayer Identification Number (TIN);(X) Electronic Funds Transfer (EFT) banking information, including routing transit number of the financial institution receiving payment and the number of the account into which funds are to be deposited;(XI) Name and telephone number of the FDA Contracting Officer Representative (COR) or other program center/office point of contact, as referenced on the purchase order; and, (XII) Any other information or documentation required by the purchase order/award.
C. QUESTIONS REGARDING INVOICES SHALL BE DIRECTED TO THE FDA AT THE TELEPHONE NUMBER PROVIDED ABOVE.
The clause at 52.212-5, Contract Terms and Conditions Required To Implement Statutes or Executive Orders-Commercial Items (Mar 2016), applies to this acquisition. The following additional FAR clauses cited in the clause are applicable to the acquisition: (b) 52.203-13, Contractor Code of Business Ethics and Conduct (Apr 2010) (Pub. L. 110-252, Title VI, Chapter 1 (41 U.S.C. 251 note)).52.219-6, Notice of Total Small Business Aside (Nov 2011) (15 U.S.C. 64452.222-21 Prohibition of Segregated Facilities (Apr 2015) 52.222-26 Equal Opportunity (Apr 2015) (E.O. 11246) 52.222-35 Equal Opportunity for Veterans (Oct 2015) (38 U.S.C. 4212)52.222-36 Equal Opportunity for Workers with Disabilities (Jul 2014) (29 U.S.C. 793)52.223-18 Encouraging Contractor Policies to Ban Text Messaging while Driving (Aug 2011) (E.O. 13513)52.232-33 Payment by Electronic Funds Transfer- System for Award Management (Jul 2013) (31 U.S.C. 3332)
FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (Dec 2013)FAR 52.217-5 Evaluation of Options (July 1990)FAR 52.217-7 Option for Increased Quantity - Separately Priced Line Item (Mar 1989)
The following HHSAR clauses apply and can be obtained at the following website: http://farsite.hill.af.mil/VFHHSAR1.html
352.203-70 Anti-lobbying (Dec 2015)352.215-70 Late proposals and revisions (Dec 2015)352.223-70 Safety and health (Dec 2015)352.224-70 Privacy Act (Dec 2015)352.233-71 Litigation and claims (Dec 2015)
The supplies delivered hereunder shall be inspected and accepted at destination by the Contracting Officer's Representative (COR) specified at award. If the supplies or services are acceptable, the COR shall promptly forward a report of inspection and acceptance to the paying office. If the supplies or services are not acceptable, the COR shall document the nonconforming items/services and immediately notify the contracting officer.
The COR name will be provided at time of award.
The COR is responsible for: (1) monitoring the Contractor's technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes in requirements; (2) interpreting the Statement of Work and any other technical performance requirements; (3) performing technical evaluation as required; (4) performing technical inspections and acceptances required by this contract; and (5) assisting in the resolution of technical problems encountered during performance.
The Contracting Officer is the only person with authority to act as agent of the Government under this contract. Only the Contracting Officer has authority to: (1) direct or negotiate any changes in the contract; (2) modify or extend the period of performance; (3) change the delivery schedule; (4) authorize reimbursement to the Contractor any costs incurred during the performance of this contract; or (5) otherwise change any terms and conditions of this contract.
It is the offeror's responsibility to monitor the internet site for the release of an amendment to the combined synopsis/solicitation (if any).
Offerors that fail to complete the required representations and certifications, or reject the terms and conditions of the solicitation, may be excluded from consideration.
All responsible sources may submit a quote, which if timely received, shall be considered. The quote shall reference solicitation number FDA-SOL-1163241. The quotes are due by email to the point of contact listed below on or before April 8, 2016 by 1:00pm ET.
Please contact Corina Genson at 240-402-5352 or email at Corina.Genson@fda.hhs.gov